EUVIMEDEUVIMED entdecken
Crossref

L26/P-912 Intraovarian use of adipose-derived stem cells in poor responders: transient endocrine changes and follicular recruitment

O. Pliekhova, N. Pylypenko, H. Matviiv, M. Fedashko, P. Kolomojets, T. Sventozelska, A. Ajdini, B. Aydin, U. Dorofeyeva

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von O. Pliekhova und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Can intraovarian administration of adipose-derived stem cells (ADSCs) induce follicular recruitment and enable follicular activation and oocyte retrieval in women with poor ovarian response Summary answer ADSC therapy induces AMH increase, FSH reduction with clinically meaningful follicular recruitment in selected group of AMA patients, creating time-limited opportunity for oocyte retrieval. What is known already Women with severely diminished ovarian reserve and repeated cancelled stimulation cycles represent one of the most challenging groups in reproductive medicine. Many patients have undergone multiple ovarian rejuvenation strategies, including platelet-rich plasma (PRP), exosome-based therapies, and other regenerative approaches, without achieving follicular recruitment or oocyte retrieval. Evidence supporting true functional ovarian recovery remains limited. Study design, size, duration Retrospective study includes 48 women with poor ovarian response. The participants, aged between 40.8 and 49.2 years (mean age 44.6 years), underwent intraovarian ADSC rejuvenation from January to May 2025, with results monitored over a six-month follow-up period. Initial assessments measured AMH and FSH levels, antral follicle count (AFC), and previous stimulation responses. Post-treatment evaluations included changes in FSH and AMH levels and the outcomes of ovarian stimulations for oocyte / embryo banking. Participants/materials, setting, methods ADSCs were isolated from autologous adipose tissue and injected intraovarianly. Study focused on women with very low ovarian reserve, characterized by AMH levels often below 0.5 ng/mL, multiple failed IVF attempts (mean of 3–5 cycles), and minimal follicular growth in prior stimulations. Participants were divided into: (A) advanced ovarian failure, (B) active responders, (C) limited responders, and (D) loss to follow-up, with outcomes compared to matched controls without stem cell therapy. Main results and the role of chance After intraovarian ADSC administration, a subset of patients demonstrated a transient increase in AMH and reduction in FSH, typically within the first 4–12 weeks after the procedure. In Group A (advanced ovarian failure, baseline FSH >30 IU/L), FSH levels decreased but functional folliculogenesis was not restored, as follicles were absent or contained no viable oocytes, similar to control cycles without ADSC. In contrast, Groups B (active responders) and C (limited responders) demonstrated follicular recruitment following multiple prior cycles without follicular growth in matched control data. One to six follicles developed during controlled ovarian stimulation, allowing retrieval of one or several mature oocytes, and embryo formation for banking. The activation period commenced between 24 to 68 days following ADSC administration and continued for 120-180 days. After this period, the ovarian response began to decrease, with hormonal markers gradually returning to baseline levels. Given the descriptive nature of the study and limited sample size, formal statistical inference regarding chance effects was restricted. Limitations, reasons for caution Retrospective study design, small sample size, heterogeneity of prior interventions, and absence of a randomised control group limit generalizability despite extended follow-up. Wider implications of the findings ADSC therapy may provide a short but clinically meaningful window for oocyte retrieval in selected poor responders who previously failed other ovarian rejuvenation strategies. Trial registration number No

Zitieren

APA

Pliekhova, O., Pylypenko, N., Matviiv, H., Fedashko, M., Kolomojets, P., Sventozelska, T., Ajdini, A., Aydin, B., & Dorofeyeva, U. (2026). L26/P-912 Intraovarian use of adipose-derived stem cells in poor responders: transient endocrine changes and follicular recruitment. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1236

Vancouver

Pliekhova O, Pylypenko N, Matviiv H, Fedashko M, Kolomojets P, Sventozelska T, et al. L26/P-912 Intraovarian use of adipose-derived stem cells in poor responders: transient endocrine changes and follicular recruitment. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1236

BibTeX
@article{Pliekhova2026,
  author = {Pliekhova, O. and Pylypenko, N. and Matviiv, H. and Fedashko, M. and Kolomojets, P. and Sventozelska, T. and Ajdini, A. and Aydin, B. and Dorofeyeva, U.},
  title = {L26/P-912 Intraovarian use of adipose-derived stem cells in poor responders: transient endocrine changes and follicular recruitment},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1236}
}
Kostenlos starten →